United Therapeutics (UTHR) CEO Rothblatt Sells $5.2M of Stock

Rothblatt's Recent Sale

Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation (NasdaqGS: UTHR), sold 9,500 shares on June 29, 2026, for about $5.2 million. The sale occurred at an average price of $545.80 per share. This planned transaction aligns with her previous insider activities and reflects her strategic financial decisions.

Insider Buying and Selling at United Therapeutics Corporation

Rothblatt has shown a pattern of buying and selling shares in recent weeks. On June 26, she sold another batch of 9,500 shares. However, just a few days before that, she purchased the same number of shares at much lower prices, further demonstrating her active engagement with her company's stock. The total value of her recent sales indicates a strong liquidity position while still maintaining a significant ownership stake.

Institutional Activity

No other institutional funds have been reported changing their positions in United Therapeutics in conjunction with Rothblatt's recent activity. This lack of peer activity suggests that Rothblatt's transactions may be viewed as individual decisions rather than indicative of broader market movements regarding the stock.

Stock Performance Context

On the day of the sale, United Therapeutics shares closed at $538.40. This price is significantly above the company's 52-week low of $409.07, suggesting a positive trend in the stock's performance. The current price also aligns closely with the stock's 200-day moving average of approximately $524.45, indicating stability in market sentiment around the company.

Recent Earnings

The company's next earnings report is scheduled for October 28, 2026. In its last earnings report, United Therapeutics recorded revenue of $3.15 billion but experienced a slight revenue growth decline of 1.9%. The net margin stood at 41.6%, and return on equity was 19.3%, showcasing overall solid financial health despite the recent revenue dip.

Analysts Set New Price Targets

On October 8, 2026, RBC Capital maintained an 'Outperform' rating for United Therapeutics, raising its price target from $677 to $708. Morgan Stanley also confirmed its 'Equal-Weight' rating with a new target of $566, up from $515. Meanwhile, BTIG upgraded the stock to a 'Buy' rating with a target of $728. The range of targets reflects analysts' confidence in the company’s growth potential.

What United Therapeutics Corporation Does

United Therapeutics Corporation focuses on developing therapies for chronic and life-threatening diseases, particularly pulmonary arterial hypertension. Its innovative products, such as Tyvaso and Remodulin, address critical medical needs for patients. Rothblatt’s recent sales indicate her ongoing strategy to manage her holdings while navigating the company’s financial landscape.

What’s Next for United Therapeutics

Investors will be watching for the upcoming earnings report on October 28, 2026, to gauge the company's performance amid market conditions. Rothblatt's trades are reminders of how insiders can influence perceptions around a company, but as always, these actions do not guarantee future performance. With a strong analyst consensus and a solid market position, United Therapeutics remains a company to watch.